Opendata, web and dolomites

Smart-4-Fabry SIGNED

Smart multifunctional GLA-nanoformulation for Fabry disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Smart-4-Fabry project word cloud

Explore the words cloud of the Smart-4-Fabry project. It provides you a very rough idea of what is the project "Smart-4-Fabry" about.

exhibits    fd    disease    deficiency    recombinant    contribution    heart    decline    industrial    fabry    excellent    protein    molecular    biotechnology    strategy    immunogenicity    representing    societal    materials    cco2    liposomal    neutral    assembly    jobs    quality    bbb    poc    smart    cross    nanoformulated    trl3    vasculopathy    shown    nervous    barriers    therapy    enzyme    biological    efficacy    free    components    cell    replacement    transport    global    detriment    alpha    nanotechnology    profile    glycosphingolipids    experimental    patients    manufacturing    health    nanoformulation    group    pd    cure    therapies    ert    definitive    lsd    samrt    trl5    lysosomal    cellular    diseases    gla    pk    incidence    intravenously    final    existence    gmps    drawbacks    accumulation    treatment    vivo    constitutes    rare    mainly    reverse    nano    disorders    kidneys    stimulate    exogenously    regulatory    administered    green    galactosidase    kets    lack    serious    membranes    storage    instability    fulfillment    preclinical   

Project "Smart-4-Fabry" data sheet

The following table provides information about the project.

Coordinator
CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. 

Organization address
address: CALLE MONFORTE DE LEMOS 5
city: MADRID
postcode: 28029
website: www.ciberisciii.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://smart4fabry.eu/
 Total cost 5˙844˙508 €
 EC max contribution 5˙844˙508 € (100%)
 Programme 1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-NMBP-2016-two-stage
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. ES (MADRID) coordinator 1˙819˙786.00
2    LEANBIO SL ES (AIGUAFREDA) participant 811˙250.00
3    NANOMOL TECHNOLOGIES SL ES (CERDANYOLA DEL VALLES) participant 565˙088.00
4    JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH AT (GRAZ) participant 556˙330.00
5    BIOKERALTY RESEARCH INSTITUTE AIE ES (ARCAUTE ALAVA) participant 533˙325.00
6    COVANCE LABORATORIES LTD UK (HARROGATE) participant 434˙395.00
7    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) participant 393˙705.00
8    AARHUS UNIVERSITET DK (AARHUS C) participant 342˙925.00
9    BIONANONET FORSCHUNGSGESELLSCHAFT MBH AT (GRAZ) participant 205˙078.00
10    DRUG DEVELOPMENT AND REGULATION SL ES (BARCELONA) participant 182˙625.00

Map

 Project objective

Lysosomal storage disorders (LSD) diseases are a group of rare diseases that currently lack a definitive cure. LSD incidence is about 1:5,000 - 1:10,000, representing a serious global health problem. In the case of Fabry LSD Disease (FD), the deficiency in α-Galactosidase A (GLA) enzyme activity results in the cellular accumulation of neutral glycosphingolipids, leading to widespread vasculopathy with particular detriment to the kidneys, heart and nervous system. The current treatment for FD is the Enzyme Replacement Therapy (ERT), in which free GLA recombinant protein is administered intravenously to patients. ERT exhibits several drawbacks mainly related to the instability, high immunogenicity and low efficacy of the exogenously administered GLA to cross biological barriers, such as cell membranes and BBB.The aim of Samrt-4-Fabry project is to achieve excellent quality control over the assembly of the different molecular components of a new liposomal nanoformulation of GLA, nano-GLA, for the treatment of Fabry disease. Nanoformulated GLA has already shown to have better PK/PD profile than free GLA and higher efficacy in vivo. Smart-4-Fabry project will advance nano-GLA from an experimental PoC (TRL3) to preclinical regulatory phase (TRL5-6). A one-step method based on the use of green cCO2, will be used for the manufacturing of this novel nanoformulation under GMPs. The final GLA nanoformulation will have tailored transport of GLA through cell membranes and BBB. Fulfillment of Smart-4-Fabry will impact on a major health problem, the existence of new therapies for rare diseases, which constitutes a priority societal challenge as shown in the H2020 Work Programmes. Another important impact is related to its contribution to support the European Strategy for KETs, which aims to reverse the decline in manufacturing as this will stimulate growth and jobs. Smart-4-Fabry is strongly focusing on three KETs: nanotechnology, industrial biotechnology and advanced materials.

 Deliverables

List of deliverables.
Use and dissemination Plan Documents, reports 2020-02-25 15:22:05
Smart-4-Fabry public website Websites, patent fillings, videos etc. 2020-02-25 15:22:05
Linkedin, Youtube, Twitter Documents, reports 2020-02-25 15:22:05

Take a look to the deliverables list in detail:  detailed list of Smart-4-Fabry deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMART-4-FABRY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMART-4-FABRY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.2.)

iNanoBIT (2017)

Integration of Nano- and Biotechnology for beta-cell and islet Transplantation

Read More  

nTRACK (2017)

Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

Read More  

NOBEL (2017)

Mobilising the European nano-biomedical ecosystem

Read More